Zero Candida Technologies, Inc. specializes in developing non-drug blue light therapy devices for treating vulvo-vaginal candidiasis. The company shows strong liquidity with a current ratio of 2.75 and minimal debt (Debt/Equity of 0.02), which are positive indicators. However, it faces concerns with negative returns on equity (-11.3%) and assets (-7.1%), reflecting operational challenges. The low market cap of $2.15M and stagnant price suggest potential undervaluation, but the negative financial metrics warrant caution for investors.
Loading financial metrics...
Company posted a loss of $-782K over the last year, representing Infinity% of revenue.
Fortress balance sheet: cash covers total debt 87×, providing significant financial flexibility.
Excellent liquidity with current ratio of 2.7x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Medical Devices companies of a similar size
Based on 2025-Q3 (September 30, 2025)